Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aspire Health vs Ivim Health

Aspire Health
Graded #346

Lower grade

vs+0.3999999999999986
Ivim Health
Graded #338

Higher grade

The verdict

Ivim Health takes it — 59.6/100 to 59.2/100, but only just.

Ivim Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Ivim Health is a telehealth weight-loss programme selling compounded semaglutide starting at $149/mo and compounded tirzepatide starting at $224/mo, each quoted with medication and programme charges included. Aspire Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAspire Health +1
45
44
Dose & formulationIvim Health +11
53
64
Clinical oversightAspire Health +5
84
79
Labs & monitoringAspire Health +14
66
52
FulfillmentIvim Health +4
61
65
Contract termsIvim Health +14
41
55
Aspire Health · left barIvim Health · right bar

The numbers

MetricAspire HealthIvim Health
WeighScore59.2/10059.6/100
GradeCC
Scorecard rank#346#338
SemaglutideNot disclosed$149/mo (starting dose, medication and programme fee, compounded)
TirzepatideNot disclosed$224/mo (starting dose, medication and programme fee, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Aspire Health

Graded #346 · C

Strengths

  • Both compounded and brand-name options (Wegovy + Zepbound) — rare among GLP-1 telehealth providers
  • Lab orders with interpretation included in LoseIt membership — not billed separately
  • Named clinical team: founded by Jenni Haan, MPAS, PA-C (18+ years experience) with four additional credentialed providers
  • Slimpossible app + secure messaging for ongoing support between provider visits
  • HSA/FSA accepted; Cherry third-party financing available for patients needing payment plans

Where it loses points

  • Membership fee ($75/month) stacks on top of separately billed medication — total spend $205–$524/month depending on dose
  • No LegitScript certification or independent third-party accreditation disclosed
  • States served not publicly listed; availability depends on individual provider licensure
  • All medication sales are final once shipped; consultation fee non-refundable once completed
  • Compounding pharmacy partner not named on any public page
Ivim Health

Graded #338 · C

Strengths

  • Both molecules are priced on one page, each quoted as medication and programme charge included rather than as a bare drug price
  • A six-month commitment brings tirzepatide down to $133/mo, and the term is published rather than hidden
  • The first month of the membership is free

Where it loses points

  • A $75/mo membership is marketed as a separate product, and whether it is charged on top of the $149 medication rate is not stated anywhere we could find
  • The $133/mo tirzepatide rate advertised on the homepage requires a six-month commitment; the month-to-month rate is $224
  • Both figures are 'starting at' rates, so the cost of a titrated dose is not published
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard